Neogen (NEOG)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$11.92+0.25%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Neogen aims for $857-$860 million revenue in fiscal 2026. It plans to finish Petrifilm manufacturing transition by November 2027. The company beat earnings in its last report. These show progress in fixing the business.
Revenue fell 4.4% in the last quarter. The company still loses money. Management changes may slow progress.
The price is about 12% above our fair value near $8. Analysts expect about 3% revenue decline. We see some growth potential but risks remain.
Breaks if: EPS falls below $0.25 in FY26
Breaks if: Transition not complete by November FY27
Breaks if: Revenue falls below $845 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on long-term growth. The current thesis state is intact, supported by recent strong financial performance and management's commitment to key initiatives.
The market seems to have priced in a significant expectations gap, indicating that NEOG may be viewed as unjustified in its current premium compared to peers. The valuation reflects a medium level of confidence in its future performance.
Management is on track with key priorities, including the transition of Petrifilm manufacturing and the planned divestiture of the Genomics business. However, there is an elevated risk due to industry peers missing earnings, which could impact NEOG's performance.
The thesis hinges on several factors, including management's ability to maintain guidance and the performance of sector bellwethers. Additionally, macroeconomic conditions, such as job growth and recession fears, could significantly impact NEOG's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports revenue growth guidance for FY26. The company increased its revenue guidance to $857-$860 million, reinforcing positive expectations. There are no significant threats noted that would weaken this outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, NEOG's fundamentals appear strong, but caution is warranted due to potential risks in the broader market. Not investment advice.